SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

Accessibility StatementSkip Navigation BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDMâ"¢ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tu ...